Applications

1723.1 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Supported

Application details

Reason for application

Highly specialised therapy – National Health Reform Agreement.

Service or technology in this application

Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Type: Therapeutic technology

Medical condition this application addresses

Acute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.

Previous applications

1723 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

Consultation survey and deadlines

  • PASC consultation: Expedited – bypassing PASC
  • MSAC consultation: Closed Friday 6 October 2023

Meetings to consider this application

  • PASC meeting: Expedited – bypassing PASC
  • ESC meeting: 5–6 October 2023
  • MSAC meeting: 23–24 November 2023